Anti-VEGF Antibody

Control
HuVec cell lysate

Evaluated by Western Blot in HuVec cell lysate.

Western Blot Analysis: 0.5 µg/mL of this antibody detected VEGF on 10 µg of HuVec cell lysate.

Detect VEGF using this Anti-VEGF Antibody validated for use in WB, IH(P).

Immunohistochemistry Analysis: 1:400 dilution from a previous lot detected VEGF in normal human placental villi tissue.

Research Category
Signaling

Research Sub Category
Growth Factors & Receptors

Other homologies: Bovine (85% sequence homology). Rat (70% sequence homology). Mouse (65% sequence homology).

This antibody recognizes VEGF at the N-terminus.

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

VEGF (Vascular endothelial growth factor, VEGFA, VEGF-A), a dimeric ligand, is among the most potent angiogenic mitogens. VEGF is secreted by tumor cells and other cells exposed to hypoxia. VEGF is a highly specific mitogen for vascular endothelial cells. Seven VEGF isoforms (a, b, c, d, e, f, g) are generated as a result of alternative splicing from a single VEGF gene. The most commonly studied isoforms are VEGF121, VEGF165, and VEGF189 (f, d and b, respectively) All seven isoforms differ in their molecular mass and in biological properties such as their ability to bind to cell-surface heparan-sulfate proteoglycans. The expression of VEGF is potentiated and is secreted by tumor cells in response to hypoxia, by activated oncogenes, and by a variety of cytokines. VEGF induces angiogenesis as well as permeabilization of blood vessels, and plays a central role in the regulation of vasculogenesis. VEGF expression correlates to the degree of tumor vascularization and with increased metastatic risk. Additionally, VEGF induces endothelial cell proliferation, promotes cell migration, and inhibits apoptosis. Consequently, inhibition of VEGF signaling abrogates the development of a wide variety of tumors.

~ 55 kDa observed. UniProtKB/Swiss-Prot P15692 (VEGFA_HUMAN) entry describes 13 isoforms produced by alternative promoter usage, alternative splicing and alternative initiation: Isoform 1 at 27.042 kDa, Isoform 2 at 25.173 kDa, Isoform 3 at 24.422 kDa, Isoform 4 at 22.314 kDa, Isoform 5 at 20.218 kDa, Isoform 6 at 20.064 kDa, Isoform 7 at 22.259 kDa, Isoform 8 at 17.219 kDa, Isoform 9 at 15.981 kDa, Isoform 10 at 40.738 kDa, Isoform 11 at 35.643 kDa, Isoform 12 at 43.597 kDa, Isoform 13 at 45.467 kDa

Epitope: N-terminus

KLH-conjugated linear peptide corresponding to human VEGF at the N-terminus.

Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.

Replaces: 07-1376

Affinity purified

Purified rabbit polyclonal in buffer containing 0.1 M Tris-Glycine (pH 7.4), 150 mM NaCl with 0.05% sodium azide.

Stable for 1 year at 2-8°C from date of receipt.